The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients

Christopher F. Sharpley, David R H Christie, Vicki Bitsika, Andrew J. Oar

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Abstract

Objective: To compare the prevalence of depressive symptoms between prostate cancer (PCa) patients who have received low-dose-rate brachytherapy (LDRB) and those receiving high-dose-rate brachytherapy (HDRB).

Method: Direct comparisons were made between the prevalence of the DSM-IV-TR symptoms of major depressive disorder (MDD) based upon Zung Self-Rating Depression Scale responses and patients’ records on 164 PCa patients from Queensland, Australia.

Results: HDRB patients had significantly greater frequency of self-reported symptoms of crying (or feeling like it) (MDD criterion 1), and restlessness and inability to sit still (MDD criterion 5), and a nonsignificant trend towards more frequent fatigue (MDD criterion 7). There was no significant association between fatigue and having received hormone therapy.

Conclusion: These three MDD symptoms, which include one of the two alternative key required symptoms (criterion 1), suggest that HDRB PCa patients may present with clinically significantly different depression profiles from their peers who receive LDRB. Treatment choices need to be focused upon possible serotonergic dysfunction as well as somatic complaints of depression. The presence of subsyndromal depression in HDRB patients also warrants consideration.

Original languageEnglish
Pages (from-to)1080-1084
Number of pages5
JournalInternational Journal of Clinical Oncology
Volume19
Issue number6
DOIs
Publication statusPublished - 10 Dec 2014

Fingerprint

Brachytherapy
Prostatic Neoplasms
Major Depressive Disorder
Depression
Fatigue
Crying
Psychomotor Agitation
Queensland
Diagnostic and Statistical Manual of Mental Disorders
Emotions
Hormones
Therapeutics

Cite this

Sharpley, Christopher F. ; Christie, David R H ; Bitsika, Vicki ; Oar, Andrew J. / The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients. In: International Journal of Clinical Oncology. 2014 ; Vol. 19, No. 6. pp. 1080-1084.
@article{410eacf00f634cffa46b82f360440342,
title = "The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients",
abstract = "Objective: To compare the prevalence of depressive symptoms between prostate cancer (PCa) patients who have received low-dose-rate brachytherapy (LDRB) and those receiving high-dose-rate brachytherapy (HDRB).Method: Direct comparisons were made between the prevalence of the DSM-IV-TR symptoms of major depressive disorder (MDD) based upon Zung Self-Rating Depression Scale responses and patients’ records on 164 PCa patients from Queensland, Australia.Results: HDRB patients had significantly greater frequency of self-reported symptoms of crying (or feeling like it) (MDD criterion 1), and restlessness and inability to sit still (MDD criterion 5), and a nonsignificant trend towards more frequent fatigue (MDD criterion 7). There was no significant association between fatigue and having received hormone therapy.Conclusion: These three MDD symptoms, which include one of the two alternative key required symptoms (criterion 1), suggest that HDRB PCa patients may present with clinically significantly different depression profiles from their peers who receive LDRB. Treatment choices need to be focused upon possible serotonergic dysfunction as well as somatic complaints of depression. The presence of subsyndromal depression in HDRB patients also warrants consideration.",
author = "Sharpley, {Christopher F.} and Christie, {David R H} and Vicki Bitsika and Oar, {Andrew J.}",
year = "2014",
month = "12",
day = "10",
doi = "10.1007/s10147-013-0647-1",
language = "English",
volume = "19",
pages = "1080--1084",
journal = "Journal of Japan Society for Cancer Therapy",
issn = "1341-9625",
publisher = "Springer",
number = "6",

}

The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients. / Sharpley, Christopher F.; Christie, David R H; Bitsika, Vicki; Oar, Andrew J.

In: International Journal of Clinical Oncology, Vol. 19, No. 6, 10.12.2014, p. 1080-1084.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - The effects of low- and high-dose-rate brachytherapy on depressive symptoms in prostate cancer patients

AU - Sharpley, Christopher F.

AU - Christie, David R H

AU - Bitsika, Vicki

AU - Oar, Andrew J.

PY - 2014/12/10

Y1 - 2014/12/10

N2 - Objective: To compare the prevalence of depressive symptoms between prostate cancer (PCa) patients who have received low-dose-rate brachytherapy (LDRB) and those receiving high-dose-rate brachytherapy (HDRB).Method: Direct comparisons were made between the prevalence of the DSM-IV-TR symptoms of major depressive disorder (MDD) based upon Zung Self-Rating Depression Scale responses and patients’ records on 164 PCa patients from Queensland, Australia.Results: HDRB patients had significantly greater frequency of self-reported symptoms of crying (or feeling like it) (MDD criterion 1), and restlessness and inability to sit still (MDD criterion 5), and a nonsignificant trend towards more frequent fatigue (MDD criterion 7). There was no significant association between fatigue and having received hormone therapy.Conclusion: These three MDD symptoms, which include one of the two alternative key required symptoms (criterion 1), suggest that HDRB PCa patients may present with clinically significantly different depression profiles from their peers who receive LDRB. Treatment choices need to be focused upon possible serotonergic dysfunction as well as somatic complaints of depression. The presence of subsyndromal depression in HDRB patients also warrants consideration.

AB - Objective: To compare the prevalence of depressive symptoms between prostate cancer (PCa) patients who have received low-dose-rate brachytherapy (LDRB) and those receiving high-dose-rate brachytherapy (HDRB).Method: Direct comparisons were made between the prevalence of the DSM-IV-TR symptoms of major depressive disorder (MDD) based upon Zung Self-Rating Depression Scale responses and patients’ records on 164 PCa patients from Queensland, Australia.Results: HDRB patients had significantly greater frequency of self-reported symptoms of crying (or feeling like it) (MDD criterion 1), and restlessness and inability to sit still (MDD criterion 5), and a nonsignificant trend towards more frequent fatigue (MDD criterion 7). There was no significant association between fatigue and having received hormone therapy.Conclusion: These three MDD symptoms, which include one of the two alternative key required symptoms (criterion 1), suggest that HDRB PCa patients may present with clinically significantly different depression profiles from their peers who receive LDRB. Treatment choices need to be focused upon possible serotonergic dysfunction as well as somatic complaints of depression. The presence of subsyndromal depression in HDRB patients also warrants consideration.

UR - http://www.scopus.com/inward/record.url?scp=84917672947&partnerID=8YFLogxK

U2 - 10.1007/s10147-013-0647-1

DO - 10.1007/s10147-013-0647-1

M3 - Article

VL - 19

SP - 1080

EP - 1084

JO - Journal of Japan Society for Cancer Therapy

JF - Journal of Japan Society for Cancer Therapy

SN - 1341-9625

IS - 6

ER -